A Retrospective Study of Clinical Efficacy of Cantharidin Cream for Verruca Plantaris
Xuelin Wu,Yanqing Hu,Yan Lu,Xiuling Ke,Kangxing Liu,Xianyi Zhou,Yongxuan Hu
DOI: https://doi.org/10.2147/IDR.S375384
2022-07-27
Infection and Drug Resistance
Abstract:Xuelin Wu, 1, 2 Yanqing Hu, 1, 2 Yan Lu, 1, 2 Xiuling Ke, 1, 2 Kangxing Liu, 1, 2 Xianyi Zhou, 1, 2 Yongxuan Hu 1, 2 1 Department of Dermatology and Venereology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, People's Republic of China; 2 Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Guangzhou, People's Republic of China Correspondence: Xianyi Zhou; Yongxuan Hu, Department of Dermatology and Venereology, The Third Affiliated Hospital of Southern Medical University, 183 West Zhongshan Road, Guangzhou, People's Republic of China, Tel/Fax + 86 20 62784561 ; + 86 20 62784560, Email ; Verruca plantaris (plantar wart) is a type of benign feet hyperplasia that is caused by a human papillomavirus (HPV) infection. In this study, we aimed to assess the clinical efficacy underlying cantharidin cream in the treatment of Verruca plantaris compared to CO 2 laser and liquid nitrogen cryotherapy. One hundred and fifty patients affected with Verruca plantaris were enrolled in this retrospective clinical study. The treatment efficacy rate in the three groups was assessed 4 and 12 weeks after treatment. After 4 weeks of treatment, 46 cases in the externally applied cantharidin cream therapy group were cured with an apparent efficiency of 92.0% (46/50). Contrarily, 42 cases in the CO 2 laser group were cured with 84.0% (42/50) efficiency, while 40 cases in the liquid nitrogen cryotherapy group were cured with an apparent efficiency of 80.0% (40/50). Although the clinical cure rate of Verruca plantaris in the Cantharidin group was greater than in the CO 2 laser group and in the liquid nitrogen cryotherapy group, there were no statistical differences found among the three groups ( P = 0.225). After 12 weeks of treatment, 43 cases in the external cantharidin cream therapy group were cured with an apparent efficiency of 86.0% (43/50). Similarly, 39 cases in the CO 2 laser group were cured with an apparent efficiency of 78.0% (39/50), while 36 cases in the liquid nitrogen cryotherapy group were cured with an apparent efficiency of 72.0% (36/50). The statistical differences among the three groups were not found ( P =0.230), but the resolution rate of warts in Cantharidin group was the highest among the three groups. The results from this study demonstrated that external cantharidin cream therapy could be served as an alternative treatment for Verruca plantaris. Keywords: cantharidin, HPV, verruca plantaris, plantar wart Verruca plantaris (plantar wart) is a type of benign epithelial hyperplasia that is caused by a human papillomavirus (HPV) infection, and affects 7% to 10% of the global population. Plantar warts are characterized by the benign proliferation of epithelial cells on the feet and are typically caused by infection with HPV type 1. 1 Asymptomatic infection with HPV occurs frequently, however most infections are controlled or cleared by cellular and humoral immune responses. Certain patient populations manifest plantar warts at a higher rate and hence require a more active treatment plan. 2 There are several clinical treatments available for Verrucae plantaris such as microwave therapy, CO 2 laser therapy, liquid nitrogen phytotherapy, surgical excision, photodynamic therapy, Candida albicans immunotherapy, podophyllotoxin, and salicylic acid therapy. 3,4 However, the side effects associated with the treatment plan for disease recurrence prevention are not ideal. 5 Cantharidin, a blister agent produced by beetles of the Meloidae coleoptera family. 3 It was used medicinally for the past 2000 years, and used to treat warts since the 1950s. 6 In recent years, it has been used in the treatment of condyloma acuminatum. 7 There are few clinical studies about Cantharidin cream for the treatment of Verruca plantaris. We used external applications of 0.025% cantharidin cream in this study to treat 50 patients with Verruca plantaris. Patients treated with CO 2 laser or liquid nitrogen cryotherapy were served as two control groups (50 patients per group). The clinical efficacy of each treatment group was explored 4 and 12 weeks posttreatment. Fifty patients with Verruca plantaris, previously diagnosed by the Department of Dermatology and Venereology, The 3rd Affiliated Hospital of Southern Medical University from 2019 to 2021, were randomly assigned to the cantharidin cream treatment group. The disease course in the patients ranged from 1 to 48 months. The patients in the cantharidin treatment group were treated with 0.025% cantharidin cream (Hainan H -Abstract Truncated-
pharmacology & pharmacy,infectious diseases